COMPASS Pathways plc
About COMPASS Pathways plc
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$287.9M
- Total assets
- $210.3M
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $179.0M
- Operating income
- -$179.0M
- Income tax
- -$2.5M
- Net income
- -$287.9M
- EPS (basic)
- $-3.08
- EPS (diluted)
- $-3.08
Balance sheet
- Total assets
- $210.3M
- Current assets
- $191.5M
- Total liabilities
- $263.2M
- Current liabilities
- $247.8M
- Shareholders’ equity
- -$52.8M
Cash flow
- Operating cash flow
- -$157.2M
- Investing cash flow
- $15.5M
- Financing cash flow
- $140.7M
- Net cash flow
- -$1.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-3.08
- Shares outstanding
- 139.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 18, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $287.9M.
- Trading 17% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review COMPASS Pathways plc.
Write a review
News about COMPASS Pathways plc
News & sentiment via Polygon.io
